What is the purpose of patient registries?

Simple Search Results for: SolirisNew SearchNavigate to Advanced Search ; Biosimilar(s) · Epysqli · eculizumab-aagh ; Interchangeable(s) · Bkemv · eculizumab-aeeb. Soliris is not expected to affect the aplastic component of anaemia in patients with PNH. Meningococcal Infection. Due to its mechanism of action, the use of ... Paroxysmal Nocturnal Hemoglobinuria (PNH). SOLIRIS is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce ... Develop highly selective and sensitive PK and ADA assays for the monoclonal antibody drug eculizumab (Soliris) using ready-made anti-idiotypic antibodies. Aug 24, 2023 ... Pioneering treatment highly effective for rare kidney disease ... A pioneering drug for a rare kidney disease prevents organ failure and ... Nov 24, 2020 ... Soliris is not intended for acute treatment of a NMOSD relapse. Route of administration: Intravenous (IV) infusion. Dosage: Patients must be ... Access to Eculizumab for patients with aHUS. NHS England published NICE guidance for the use of Eculizumab for treating in aHUS in January 2015. Eculizumab is an oral medication designed to block the action of endothelin, a natural substance in the body that narrows blood vessels. By inhibiting ... Sep 21, 2024 ... Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), and myasthenia gravis. 2. How ... This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and to evaluate the effectiveness of Soliris ...